Erratum to: Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab

Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 2013 Sep;71(9):1532–40. doi: 10.1016/j.joms.2013.03.019. Epub 2013 May 1.

Author information

Authors and Affiliations

Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Via Venezia 16, 15121, Alessandria, Italy
Vittorio Fusco
Department of Surgery, Section of Oral and Maxillofacial Surgery, University and Hospital Trust of Verona, P.le L.A. Scuro 10, Verona, 37134, Italy
Alberto Bedogni
Department of Surgical, Oncological and Oral Sciences- Sector of Oral Medicine, Palermo University, Via del Vepro 129, Palermo, 90127, Italy
Giuseppina Campisi

Authors

Vittorio Fusco
View author publications
You can also search for this author in PubMed Google Scholar
Alberto Bedogni
View author publications
You can also search for this author in PubMed Google Scholar
Giuseppina Campisi
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vittorio Fusco.

Additional information

The online version of the original article can be found at http://dx.doi.org/10.1007/s00520-014-2159-6.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fusco, V., Bedogni, A. & Campisi, G. Erratum to: Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab. Support Care Cancer 22, 1739 (2014). https://doi.org/10.1007/s00520-014-2247-7

Download citation

Published: 26 April 2014
Issue Date: July 2014
DOI: https://doi.org/10.1007/s00520-014-2247-7

Use our pre-submission checklist

Avoid common mistakes on your manuscript.